Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GlaxoSmithKline update: influenza A (H1N1)
GSK committed to supporting governments and health authorities around the world to respond to the emergence of the new H1N1 strain.
Emergence of a new H1N1 influenza A strain (swine influenza)
GSK is closely monitoring H1N1 strain in Mexico, US, Canada, France, Spain & New Zealand. WHO stated, situation a cause for concern.
Large, long-term study shows dutasteride reduced prostate cancer risk in men at increased risk of the disease
Primary endpoint achieved in REDUCE study as presented at American Urological Association
GlaxoSmithKline and Stiefel to create new world-leading specialist dermatology business
Stiefel, the world's largest independent dermatology company, acquired by GSK in deal valued at up to $3.6 billion.
GlaxoSmithKline launches alli® (orlistat 60 mg)
GSK announced, first clinically proven over the counter weight loss aid is available in pharmacies across Europe.
GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company
Creates a new focused HIV business with the sustainability to deliver significant improvements in treatment, access and shareholder value.
Synflorix™, GlaxoSmithKline’s pneumococcal vaccine, receives European authorisation
Protection now possible against three pneumococcal strains not covered by currently available vaccine.
GSK submits Tyverb®/Tykerb® (lapatinib) for first-line treatment of metastatic breast cancer in Europe, US
GSK announced, submission of 2 applications to expand the use of lapatinib, therapy regimen for metastatic breast cancer.
Cervarix® U.S. regulatory update
GlaxoSmithKline submits final study data to FDA for cervical cancer vaccine
GSK publishes 2008 Corporate Responsibility Report
Details on new proposals to tackle diseases of the developing world.
GlaxoSmithKline announces sale of shares in Quest Diagnostics Inc.
GSK announces it's sold 5,749,157 shares of common stock, par value of $0.01 per share of Quest Diagnostics Inc.
NICE refuses funding for advanced breast cancer treatment, Tyverb® (lapatinib)
NICE issued appraisal against NHS funding for Tyverb, treatment for breast cancer (ErbB2-positive).1.
GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer
GSK announced submission of MAA to EMEA for pazopanib, oral therapy for metastatic renal cell carcinoma (RCC).
GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)
GSK announced start of the Phase III clinical trial programme of GLP-1 agonist Syncria in men and women with type 2 diabetes.
GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer
GSK & Genmab announced submission of MAA to EMEA for Arzerra, treatment of CLL, it targets a binding site on the CD20 molecule of B-cells.
GlaxoSmithKline and Idenix Pharmaceuticals sign worldwide license agreement for IDX899, a novel NNRTI for the treatment of HIV
GSK & Idenix announced agreement granting GSK exclusive worldwide rights to IDX899, a NNRTI in Phase II, treatment of HIV/AIDS.
Results announcement for the fourth quarter 2008
See the quarterly results page for more information.
GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma
Data increase confidence in the Horizon development programme
GlaxoSmithKline plc, announces board changes
GSK announces, Mr. James Murdoch has been appointed as a Non-Executive Director and will join the Board of the Company from 20/05/09.
Deirdre Connelly to join GSK as President, North American Pharmaceuticals
GSK announced, Deirdre Connelly will join the company as President, North American Pharmaceuticals, effective Monday 9 February 2009.